公司新闻 - 亚科因（Abbkine）—服务于细胞和蛋白研究全球用户

首页
技术中心
产品文献

或

货号	产品名称	文献标题	IF	杂志名称
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	Reduction of eEF2 kinase alleviates the learning and memory impairment caused by acrylamide		Research Square
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	Bifunctional Microbead Carriers with Magnetic Response and Plasmonic Fluorescence Enhancement	1	Journal of Nanoscience and Nanotechnology, 19
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	The effect of regulating MCU expression on experimental ischemic brain injury	5	Experimental Neurology
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	Zinc alleviates cadmium-induced reproductive toxicity via regulating ion homeostasis, metallothionein expression, and inhibiting mitochondria-mediated …	7	Ecotoxicology and Environmental Safety
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	Butyrate promotes oral squamous cell carcinoma cells migration, invasion and epithelial-mesenchymal transition	2	PeerJ
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma Cells.
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	Exosomes derived from stem cells from apical papilla promote craniofacial soft tissue regeneration by enhancing Cdc42-mediated vascularization	7	Stem Cell Research & Therapy
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression	13	Journal of Experimental & Clinical Cancer Research
A23920	山羊抗兔IgG二抗，远红外DyLight 800荧光标记	Pyk2/MCU Pathway as a New Target for Reversing Atherosclerosis	7	Front Cell Dev Biol
A24211	IFKine驴抗小鼠IgG二抗，绿色荧光标记（IF实验优化）	Trpv4 regulates Nlrp3 inflammasome via SIRT1/PGC-1α pathway in a cuprizone-induced mouse model of demyelination	5	Exp Neurol

首页上一页 244 245 246 247 248 249 下一页尾页

赋能细胞研究与治疗 Enabling cell research and therapy

联系我们

全国服务热线： 400-6800-830

订购邮箱： service@abbkine.com

联系地址：武汉光谷生物医药加速器17号楼1号房2-3层

友情链接：

Copyright ©Abbkine Scientific Co., Ltd- 鄂ICP备10204150号-5

意见反馈

 在线咨询

扫码关注

微信公众号

返回顶部